A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors

Trial Profile

A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Pazopanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
    • 19 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 21 Nov 2014 Interim results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top